Maria Teresa Ionta - Concepedia

Author

Maria Teresa Ionta

Also Known As

B. Massidda, Ionta, Maria Teresa, M T Ionta, M. Ionta, M.T. Ionta, M.T. Maria Teresa Ionta, MARIA TERESA IONTA, Maria T Ionta, Maria Teresa Ionta

Publications

749

Citations

H-Index

Concepts

All Affiliations

University of Cagliari Istituti di Ricovero e Cura a Carattere Scientifico Mario Negri Institute for Pharmacological Research Fondazione IRCCS Istituto Nazionale dei Tumori Ospedale Papa Giovanni XXIII

About

Maria Teresa Ionta is an author at University of Cagliari specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	242
2	Health Sciences	2	2	71
3	Nursing	1	1	15
4	Allergy	1	1	17
5	Allergy Medicine	1	1	17

Maria Teresa Ionta

Publications

619

Citations

H-Index

Page 1

	Year	Citations
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo, Annals of Oncology Surgical OncologyOncologyGastrointestinal OncologyMedicineFolinic Acid	2014	89
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients Annamaria Ruzzo, Francesco Graziano, Fabio Galli, British Journal of Cancer	2017	68
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study Grazia Palomba, Valentina Doneddu, Antonio Cossu, Journal of Translational Medicine	2016	55
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial Sara Lonardi, Alberto Sobrero, Gerardo Rosati, Annals of Oncology Tosca TrialGastrointestinal OncologyMedicinePhase Iii TrialClinical Trials	2016	54
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved? Fabiana Pani, Francesco Atzori, Germana Baghino, Thyroid	2015	45
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients Annamaria Ruzzo, Francesco Graziano, Fabio Galli, Scientific Reports	2014	41
Cancer patients as `experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO) Massimo Costantini, Emanuela Mencaglia, Paola Di Giulio, Quality of Life Research	2000	36
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Adriana Romiti, B. Massidda, Maria Teresa Ionta, PubMed	2002	31
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Mario Airoldi, Dino Amadori, Sandro Barni, PubMed Breast OncologyAnthracycline-containing RegimensMedicineSynthetic ReviewPharmacology	2012	21
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy Annamaria Ruzzo, Francesco Graziano, Francesca Galli, Scientific Reports	2019	19

Page 1